Research Papers:

eIF3a improve cisplatin sensitivity in ovarian cancer by regulating XPC and p27Kip1 translation

Yu Zhang, Jing-Jing Yu, Yan Tian, Zheng-Zheng Li, Cai-Yi Zhang, Shu-Fen Zhang, Lan-Qin Cao, Yi Zhang, Chen-Yue Qian, Wei Zhang, Hong-Hao Zhou, Ji-Ye Yin and Zhao-Qian Liu _

PDF  |  HTML  |  How to cite

Oncotarget. 2015; 6:25441-25451. https://doi.org/10.18632/oncotarget.4555

Metrics: PDF 2178 views  |   HTML 2189 views  |   ?  


Yu Zhang1,3, Jing-Jing Yu3, Yan Tian3, Zheng-Zheng Li3, Cai-Yi Zhang3, Shu-Fen Zhang3, Lan-Qin Cao3, Yi Zhang3, Chen-Yue Qian1,2, Wei Zhang1,2, Hong-Hao Zhou1,2, Ji-Ye Yin1,2, Zhao-Qian Liu1,2

1Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, P. R. China

2Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, P. R. China

3Department of Obstetrics & Gynecology, Xiangya Hospital, Central South University, Changsha 410008, P. R. China

Correspondence to:

Zhao-Qian Liu, e-mail: [email protected]

Ji-Ye Yin, e-mail: [email protected]

Keywords: eIF3a, platinum, ovarian cancer, drug resistance, XPC

Received: April 30, 2015     Accepted: June 29, 2015     Published: July 11, 2015


The eukaryotic translation initiation factor 3a (eIF3a) is one of the core subunits of the translation initiation complex eIF3, responsible for ribosomal subunit joining and mRNA recruitment to the ribosome. Our previous study identified that it was correlated with platinum response in lung cancer. The current study aims to test the hypothesis that eIF3a may affect the drug response and prognosis of ovarian cancer patients receiving platinum-based chemotherapy by regulating xeroderma pigmentosum complementation group C (XPC) and p27Kip1. Immunohistochemistry and western blot was used to determine the expression of eIF3a in 126 human ovarian cancer tissues followed by association analysis of eIF3a expression with patient’s response and survival. Ectopic over-expression and RNA interference knockdown of eIF3a were carried out in A2780/cisplatin (DDP) and its parental A2780 cells, respectively, to determine the effect of altered eIF3a expression on cellular response to cisplatin by employing MTT assay. Western Blot analyses were also carried out to determine the regulation of eIF3a on XPC and p27Kip1. eIF3a expression was associated with response of ovarian cancer patients to DDP-based chemotherapy and their survival. Overexpression and knockdown of eIF3a increased and decreased the cellular response to cisplatin in A2780/DDP and A2780 cells, respectively. In addition, XPC and p27Kip1 were down regulated by eIF3a. eIF3a improves ovarian cancer patients’ response to DDP-based chemotherapy via down regulating XPC and p27Kip1.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 4555